|
Premium Company Profile - Idenix Pharmaceuticals, Inc. (Datamonitor)
Market: Healthcare and Medical
Published Date: 31/10/2007
Market Research Report Title: Premium Company Profile - Idenix Pharmaceuticals, Inc.
Table of Contents: View
Report Type: Company Profile
Country: Global
Number of Pages: 43
|
Enquire about Report |
Summary: Introduction
Idenix Pharmaceuticals develops drugs for the treatment of human viral and other infectious diseases. Novartis is the major shareholder of the company owning 56% of Idenix and has development and worldwide marketing rights for Idenix′s HBV and HCV franchise.
Scope
Contains corporate strategy, value chain presence and SWOT AnalysisProvides detailed business description, segment analysis, 5-year financial trends, key products and key competitorsIncludes information on suppliers/ partners, shareholding structure and key employees with biographiesHighlights
Idenix currently focuses on the development and commercialization of drugs for the treatment of hepatitis C and human immuno viral infections. The company′s only approved product, Tyzeka/Sebivo for the hepatitis B virus, is developed, manufactured and marketed by Novartis and Idenix receives royalties on the product salesThe company′s total revenues increased at a CAGR of 110% from $3 million to $67 million during 2002-2006, representing an absolute growth of +$64 million. As the company launched approved product Tyzeka in October 2006, it recorded $0.6 million of revenues from product sales in fiscal 2006Idenix′s revenues are forecast to increase from $67 million in 2006 to $198 million in 2010, growing at a CAGR of 31%. This represents an absolute growth of +$131 million during the period. Collaboration and license revenues from Novartis are expected to be the largest contributor to the company′s overall revenue growthReasons to Purchase
Access all the important information and analysis on the company in a single reportUnderstand company′s strengths, weaknesses, opportunities and threats along with business strategy and value chainGain access to company′s adjusted five year financial data along with key ratios and market capitalization
Reports are normally delivered on the same day, via email, if purchased by debit/credit card. Reports purchased by invoice will be released when payment has been received. When you place an order through Google Checkout, Google Checkout will display a price approximation in your local currency. Keep in mind that you'll still be charged in the currency displayed on companiesandmarkets.com. Your debit/credit card company might convert the charge to your local currency and may also add additional fees that are not reflected in the approximate price displayed.
www.companiesandmarkets.com is a central source of market research reports from the world’s leading analysts and report publishers. Companiesandmarkets.com contains a comprehensive range of specialised market research reports from leading publishers for all market sectors.
